BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17253973)

  • 1. Predominant immature CD8alpha+ dendritic cells prevent graft-vs.-host disease but do not increase the risk of leukemia recurrence.
    Xu L; Duan L; Cao K; Yuan G; Peng Y; Huang X; Xiang P; Li S
    Eur J Haematol; 2007 Mar; 78(3):235-45. PubMed ID: 17253973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental study on immunotherapy with dendritic cell in leukemic mice model].
    Li XX; Chen XL; Ma DX; Liu CS; He XP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):73-7. PubMed ID: 16732955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal polypeptide induces regulatory dendritic cells that prevent acute graft versus host disease and leukemia relapse after bone marrow transplantation.
    Delgado M; Chorny A; Ganea D; Gonzalez-Rey E
    Ann N Y Acad Sci; 2006 Jul; 1070():226-32. PubMed ID: 16888171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal in vitro culture conditions for murine predominant immature CD8a+ dendritic cells.
    Na N; Xu L; Cao KY; Luo Y; Yuan GQ; Xiang P; Hong LQ; Li SN
    Chin Med J (Engl); 2009 Feb; 122(3):344-8. PubMed ID: 19236816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of third-party tolerogenic dendritic cells in the prevention of acute graft-versus-host-disease following allogeneic bone marrow transplantation in mice].
    Li GP; Yang J; Hao J; Yang YM; Ren YN; Xie RF; Fan HH; Qian KC
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):461-6. PubMed ID: 22967381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of murine acute graft-versus-host disease by recipient-derived TGFbeta1-treated dendritic cells.
    Mou HB; Lin MF; Cen H; Huang H; Cai Z
    Transplant Proc; 2004 Jun; 36(5):1604-6. PubMed ID: 15251394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone marrow transplantation: Reminiscence of gut-associated acute graft-versus-host reaction.
    Schmitt M; Taniguchi M; Yoshida T; Miyahara Y; Gu X; Mukai K; Yagita H; Dohner H; Shiku H
    Int J Oncol; 2002 Oct; 21(4):795-801. PubMed ID: 12239618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of HGF on graft-versus-host disease and graft-versus-leukemia after allogeneic bone marrow transplantation in acute lymphoblastic leukemia mice].
    Xia YJ; Gao QP; Wan CC; Cheng FJ; Liu ZX; Guo RC
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):404-7. PubMed ID: 16251021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-derived CD8⁺ dendritic cells protect against acute graft-versus-host disease after experimental allogeneic bone marrow transplantation.
    Weber M; Rudolph B; Stein P; Yogev N; Bosmann M; Schild H; Radsak MP
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1696-704. PubMed ID: 25132527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of graft-versus-host disease by lentiviral-mediated expression of herpes simplex virus-thymidine kinase and ganciclovir treatment.
    Xu K; Zhu F; Du B; Gao F; Cheng H; Pan X
    Transplant Proc; 2008 Oct; 40(8):2665-9. PubMed ID: 18929831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity.
    O'Connell PJ; Son YI; Giermasz A; Wang Z; Logar AJ; Thomson AW; Kalinski P
    Eur J Immunol; 2003 Jul; 33(7):2007-13. PubMed ID: 12884867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of murine acute graft-versus-host disease by recipient-derived paired immunoglobulin-like receptor B lentivirus-transfected dendritic cells.
    Zhao J; Luo Y; Wang X; Zhou H; Li Q; You Y; Zou P
    Acta Haematol; 2010; 124(3):134-40. PubMed ID: 20881379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
    Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
    Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
    Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
    Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.